


§§1.821-1.825 is a disk copy of the Sequence Listing. The disk copy of the Sequence Listing, file "1752-0151P.ST25.TXT", is identical to the paper copy, except that it lacks formatting.

The specification has been amended to refer to the sequences by their "SEQ ID NO". The paragraph beginning on page 71, line 21, has also been amended to correct a typographical error in order to clarify the method in which the MFL mRNA template was obtained. The descriptions of the artificial sequences, as provided in the enclosed Sequence Listing, are fully supported by the Specification as filed. The publication information for SEQ ID NOS: 2 - 3 is also provided in the enclosed Sequence Listing. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,  
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr., Reg. No. 28,977

GMM/LPS/CAV

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachments:

Disk Copy of Sequence Listing  
Paper Copy of Sequence Listing  
Copy of Notification  
Version With Markings Showing Changes Made

(Rev. 03/27/01)



**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Please replace the paragraph beginning on page 39, line 18, with the following rewritten paragraph:

[0068] There is known a method of purifying cyclic nucleotide-gated (CNG) channel, which is a protein originating in bovine retina, by using a monoclonal antibody PMc 6E7 (N-terminal domain of  $\alpha$  subunit: 63-kDa polypeptide) (R. S. Molday and L. L. Molday, Purification, Characterization, and Reconstitution of Cyclic Nucleotide-Gated Channels. Methods in Enzymology 294: 246-260, 1999). Sepharose 2B (Pharmacia) carrying the monoclonal antibody fixed thereon is used as an adsorbent. To elute the target protein, use is made of 6E7 competing peptide which is a peptide competitively binding to the monoclonal antibody and having an amino acid sequence Ser- Asn- Lys- Glu- Gln- Glu- Pro- Lys- Glu- Lys- Lys- Lys- Lys- Lys (**SEQ ID NO:1**). This combination is also usable in the present invention.

Please replace the paragraph beginning on page 42, line 1, with the following rewritten paragraph:

[0071] In this process with the use of the binding of Strep-tag to streptavidin, use is made as the Strep-tag, for example, Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly (**SEQ ID NO:2**) or Asn-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (Strep-tag II) (**SEQ ID NO:3**). A Strep-tagged protein such as DHFR (dihydrofolate reductase) is synthesized in a cell-free system. Then it is purified by adsorbing by fixed streptavidin or Strep Tactin. As an eluent, desthiobiotin is employed.

Please replace the paragraph beginning on page 71, line 21, with the following rewritten paragraph:

[0108] To obtain a template for MFL mRNA[, a DNA sequence] AUGUUCUUGUAA (**SEQ ID NO:4**), **a DNA sequence** (translated into fMet-Phe-Leu-Stop; formylmethionine-phenylalanine-leucine-stop codon; hereinafter referred to simply as MFL) was constructed as follows. An oligonucleotide A: 5'-Tatgttcttgaac (**SEQ ID NO:5**) was annealed with another oligonucleotide B: 5'-TCGAgttacaagaaca (**SEQ ID NO:6**) to give a double-stranded DNA

containing NdeI and XhoI sequences. Next, this DNA was cloned into the NdeI and XhoI sites of a plasmid vector pET29a (Novagen). The resultant plasmid transcribed as in the above-described case of DHFR gene.